Inositide signaling in the nucleus: From physiology to pathology

Advances in Enzyme Regulation

Volumn 50, Issue 1, 2010, Pages 2-11

  Cocco, Lucio ^a   Follo, Matilde Y ^a   Faenza, Irene ^a   Billi, Anna Maria ^a   Ramazzotti, Giulia ^a   Martelli, Alberto M ^a,b   Manzoli, Lucia ^a   Weber, George ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b CNR   (Italy)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL; PHOSPHOLIPASE C BETA;

ANIMAL; BLOOD DISEASE; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; HEMATOLOGIC NEOPLASMS; HUMANS; PHOSPHATIDYLINOSITOLS; PHOSPHOLIPASE C BETA; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION;

EID: 77951741017     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2009.10.007     Document Type: Article

References (79)

1. Atallah E., Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest 2008, 26:208-216.
2. Bavelloni A., Faenza I., Cioffi G., Piazzi M., Parisi D., Matic I., et al. Proteomic-based analysis of nuclear signaling: PLCbeta1 affects the expression of the splicing factor SRp20 in Friend erythroleukemia cells. Proteomics 2006, 6:5725-5734.
3. Bernasconi P., Cavigliano P.M., Boni M., Calatroni S., Klersy C., Giardini I., et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia 2003, 17:2107-2112.
4. Bernasconi P., Boni M., Cavigliano P.M., Calatroni S., Giardini I., Rocca B., et al. Clinical relevance of cytogenetics in myelodysplastic syndromes. Ann N Y Acad Sci 2006, 1089:395-410.
5. Billi A.M., Cocco L., Martelli A.M., Gilmour R.S., Weber G. Tiazofurin-induced changes in inositol lipid cycle in nuclei of Friend erythroleukemia cells. Biochem Biophys Res Commun 1993, 195:8-12.
6. Boultwood J., Wainscoat J.S. Gene silencing by DNA methylation in haematological malignancies. Br J Haematol 2007, 138:3-11.
7. Caceres J.F., Misteli T., Screaton G.R., Spector D.L., Krainer A.R. Role of the modular domains of SR proteins in subnuclear localization and alternative splicing specificity. J Cell Biol 1997, 138:225-238.
8. Caceres J.F., Screaton G.R., Krainer A.R. A specific subset of SR proteins shuttles continuously between the nucleus and the cytoplasm. Genes Dev 1998, 12:55-66.
9. Cenciarelli C., De Santa F., Puri P.L., Mattei E., Ricci L., Bucci F., et al. Critical role played by cyclin D3 in the MyoD-mediated arrest of cell cycle during myoblast differentiation. Mol Cell Biol 1999, 19:5203-5217.
10. Cocco L., Gilmour R.S., Ognibene A., Letcher A.J., Manzoli F.A., Irvine R.F. Synthesis of polyphosphoinositides in nuclei of Friend cells. Evidence for polyphosphoinositide metabolism inside the nucleus which changes with cell differentiation. Biochem J 1987, 248:765-770.
11. Cocco L., Faenza I., Follo M.Y., Ramazzotti G., Gaboardi G.C., Billi A.M., et al. Inositide signaling: nuclear targets and involvement in myelodysplastic syndromes. Adv Enzyme Regul 2008, 48:2-9.
12. Cocco L., Faenza I., Follo M.Y., Billi A.M., Ramazzotti G., Papa V., et al. Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology. Adv Enzyme Regul 2009, 49:2-10.
13. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Kohler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002, 100:2957-2964.
14. Divecha N., Letcher A.J., Banfic H.H., Rhee S.G., Irvine R.F. Changes in the components of a nuclear inositide cycle during differentiation in murine erythroleukaemia cells. Biochem J 1995, 312(Pt 1):63-67.
15. Evangelisti C., Riccio M., Faenza I., Zini N., Hozumi Y., Goto K., et al. Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts. J Cell Physiol 2006, 209:370-378.
16. Faenza I., Matteucci A., Manzoli L., Billi A.M., Aluigi M., Peruzzi D., et al. A role for nuclear phospholipase Cbeta 1 in cell cycle control. J Biol Chem 2000, 275:30520-30524.
17. Faenza I., Matteucci A., Bavelloni A., Marmiroli S., Martelli A.M., Gilmour R.S., et al. Nuclear PLCbeta(1) acts as a negative regulator of p45/NF-E2 expression levels in Friend erythroleukemia cells. Biochim Biophys Acta 2002, 1589:305-310.
18. Faenza I., Bavelloni A., Fiume R., Lattanzi G., Maraldi N.M., Gilmour R.S., et al. Up-regulation of nuclear PLCbeta1 in myogenic differentiation. J Cell Physiol 2003, 195:446-452.
19. Faenza I., Bavelloni A., Fiume R., Santi P., Martelli A.M., Maria Billi A., et al. Expression of phospholipase C beta family isoenzymes in C2C12 myoblasts during terminal differentiation. J Cell Physiol 2004, 200:291-296.
20. Faenza I., Ramazzotti G., Bavelloni A., Fiume R., Gaboardi G.C., Follo M.Y., et al. Inositide-dependent phospholipase C signaling mimics insulin in skeletal muscle differentiation by affecting specific regions of the cyclin D3 promoter. Endocrinology 2007, 148:1108-1117.
21. Faenza I., Bregoli L., Ramazzotti G., Gaboardi G., Follo M.Y., Mongiorgi S., et al. Nuclear phospholipase C beta1 and cellular differentiation. Front Biosci 2008, 13:2452-2463.
22. Farah C.S., Reinach F.C. The troponin complex and regulation of muscle contraction. Faseb J 1995, 9:755-767.
23. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
24. Fiume R., Faenza I., Matteucci A., Astolfi A., Vitale M., Martelli A.M., et al. Nuclear phospholipase C beta1 (PLCbeta1) affects CD24 expression in murine erythroleukemia cells. J Biol Chem 2005, 280:24221-24226.
25. Follo M.Y., Bosi C., Finelli C., Fiume R., Faenza I., Ramazzotti G., et al. Real-time PCR as a tool for quantitative analysis of PI-PLCbeta1 gene expression in myelodysplastic syndrome. Int J Mol Med 2006, 18:267-271.
26. Follo M.Y., Mongiorgi S., Bosi C., Cappellini A., Finelli C., Chiarini F., et al. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res 2007, 67:4287-4294.
27. Follo M.Y., Finelli C., Bosi C., Martinelli G., Mongiorgi S., Baccarani M., et al. PI-PLCbeta-1 and activated Akt levels are linked to azacitidine responsiveness in high-risk myelodysplastic syndromes. Leukemia 2008, 22:198-200.
28. Follo M.Y., Finelli C., Clissa C., Mongiorgi S., Bosi C., Martinelli G., et al. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol 2009, 27:782-790.
29. Follo M.Y., Finelli C., Mongiorgi S., Clissa C., Bosi C., Testoni N., et al. Reduction of phosphoinositide-phospholipase C (PI-PLC) beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci USA 2009, 106(39):16811-16816.
30. Gohring G., Karow A., Steinemann D., Wilkens L., Lichter P., Zeidler C., et al. Chromosomal aberrations in congenital bone marrow failure disorders-an early indicator for leukemogenesis?. Ann Hematol 2007, 86:733-739.
31. Gondek L.P., Tiu R., O'Keefe C.L., Sekeres M.A., Theil K.S., Maciejewski J.P. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 2008, 111:1534-1542.
32. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
33. Griffiths E.A., Gore S.D. DNA methyltransferase inhibitors: class effect or unique agents?. Leuk Lymphoma 2008, 49:650-651.
34. Gronbaek K., Hother C., Jones P.A. Epigenetic changes in cancer. Apmis 2007, 115:1039-1059.
35. Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008, 87:515-526.
36. Irvine R.F. Nuclear inositide signalling - expansion, structures and clarification. Biochim Biophys Acta 2006, 1761:505-508.
37. Itzykson R., Gardin C., Fenaux P. Meeting report: myelodysplastic syndromes at ASH 2007. Leukemia 2008, 22:893-897.
38. Jabbour E., Issa J.P., Garcia-Manero G., Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer 2008, 112:2341-2351.
39. Jabbour E., Kantarjian H.M., Koller C., Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008, 112:1089-1095.
40. Jiang Y., Dunbar A., Gondek L.P., Mohan S., Rataul M., O'Keefe C., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113:1315-1325.
41. Kantarjian H.M., O'Brien S., Huang X., Garcia-Manero G., Ravandi F., Cortes J., et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007, 109:1133-1137.
42. Kato J.Y., Sherr C.J. Inhibition of granulocyte differentiation by G1 cyclins D2 and D3 but not D1. Proc Natl Acad Sci U S A 1993, 90:11513-11517.
43. Kelaidi C., Park S., Brechignac S., Mannone L., Vey N., Dombret H., et al. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res 2008, 32:1049-1053.
44. Khan R., Schmidt-Mende J., Karimi M., Gogvadze V., Hassan M., Ekstrom T.J., et al. Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol 2008, 36:149-157.
45. La Cour L.F., Chayen J., Gahan P.S. Evidence for lipid material in chromosomes. Exp Cell Res 1958, 14:469-485.
46. Lassar A., Munsterberg A. Wiring diagrams: regulatory circuits and the control of skeletal myogenesis. Curr Opin Cell Biol 1994, 6:432-442.
47. Liberona J.L., Powell J.A., Shenoi S., Petherbridge L., Caviedes R., Jaimovich E. Differences in both inositol 1,4,5-trisphosphate mass and inositol 1,4,5-trisphosphate receptors between normal and dystrophic skeletal muscle cell lines. Muscle Nerve 1998, 21:902-909.
48. Lo Vasco V.R., Calabrese G., Manzoli L., Palka G., Spadano A., Morizio E., et al. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004, 18:1122-1126.
49. Lopez J., Percharde M., Coley H.M., Webb A., Crook T. The context and potential of epigenetics in oncology. Br J Cancer 2009, 100:571-577.
50. Los A.P., Vinke F.P., de Widt J., Topham M.K., van Blitterswijk W.J., Divecha N. The retinoblastoma family proteins bind to and activate diacylglycerol kinase zeta. J Biol Chem 2006, 281:858-866.
51. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies. Blood 2008, 112:965-974.
52. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91:1588-1590.
53. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
54. Manzoli F.A., Capitani S., Maraldi N.M., Cocco L., Barnabei O. Chromatin lipids and their possible role in gene expression. A study in normal and neoplastic cells. Adv Enzyme Regul 1978, 17:175-194.
55. Manzoli F.A., Martelli A.M., Capitani S., Maraldi N.M., Rizzoli R., Barnabei O., et al. Nuclear polyphosphoinositides during cell growth and differentiation. Adv Enzyme Regul 1989, 28:25-34.
56. Manzoli L., Billi A.M., Gilmour R.S., Martelli A.M., Matteucci A., Rubbini S., et al. Phosphoinositide signaling in nuclei of Friend cells: tiazofurin down-regulates phospholipase C beta 1. Cancer Res 1995, 55:2978-2980.
57. Mariappan I., Parnaik V.K. Sequestration of pRb by cyclin D3 causes intranuclear reorganization of lamin A/C during muscle cell differentiation. Mol Biol Cell 2005, 16:1948-1960.
58. Martelli A.M., Billi A.M., Gilmour R.S., Neri L.M., Manzoli L., Ognibene A., et al. Phosphoinositide signaling in nuclei of Friend cells: phospholipase C beta down-regulation is related to cell differentiation. Cancer Res 1994, 54:2536-2540.
59. Matteucci A., Faenza I., Gilmour R.S., Manzoli L., Billi A.M., Peruzzi D., et al. Nuclear but not cytoplasmic phospholipase C beta 1 inhibits differentiation of erythroleukemia cells. Cancer Res 1998, 58:5057-5060.
60. Mohamedali A., Gaken J., Twine N.A., Ingram W., Westwood N., Lea N.C., et al. Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes. Blood 2007, 110:3365-3373.
61. Mufti G.J., Chen T.L. Changing the treatment paradigm in myelodysplastic syndromes. Cancer Control 2008, 15(Suppl):14-28.
62. Muller-Thomas C., Schuster T., Peschel C., Gotze K.S. A limited number of 5-azacitidine cycles can be effective treatment in MDS. Ann Hematol 2009, 88:213-219.
63. Nimer S.D. Myelodysplastic syndromes. Blood 2008, 111:4841-4851.
64. Nyakern M., Tazzari P.L., Finelli C., Bosi C., Follo M.Y., Grafone T., et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006, 20:230-238.
65. Park S., Grabar S., Kelaidi C., Beyne-Rauzy O., Picard F., Bardet V., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
66. Pfeilstocker M., Karlic H., Nosslinger T., Sperr W., Stauder R., Krieger O., et al. Myelodysplastic syndromes, aging, and age: correlations, common mechanisms, and clinical implications. Leuk Lymphoma 2007, 48:1900-1909.
67. Ramazzotti G., Faenza I., Gaboardi G.C., Piazzi M., Bavelloni A., Fiume R., et al. Catalytic activity of nuclear PLC-beta(1) is required for its signalling function during C2C12 differentiation. Cell Signal 2008, 20:2013-2021.
68. Raza A., Reeves J.A., Feldman E.J., Dewald G.W., Bennett J.M., Deeg H.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111:86-93.
69. Ross E.M., Mateu D., Gomes A.V., Arana C., Tran T., Litosch I. Structural determinants for phosphatidic acid regulation of phospholipase C-beta1. J Biol Chem 2006, 281:33087-33094.
70. Saeki K., Yasugi E., Okuma E., Breit S.N., Nakamura M., Toda T., et al. Proteomic analysis on insulin signaling in human hematopoietic cells: identification of CLIC1 and SRp20 as novel downstream effectors of insulin. Am J Physiol Endocrinol Metab 2005, 289:E419-E428.
71. Schmelz K., Wagner M., Dorken B., Tamm I. 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005, 114:683-695.
72. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440.
73. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
74. Slovak M.L., Dewald G.W. International Working Group on MDS cytogenetics: October 2007 meeting report. Leuk Res 2008, 32:1329-1332.
75. Stresemann C., Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 2008, 123:8-13.
76. Tamm I., Wagner M., Schmelz K. Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Ann Hematol 2005, 84(Suppl 1):47-53.
77. Wang Z., Sicinski P., Weinberg R.A., Zhang Y., Ravid K. Characterization of the mouse cyclin D3 gene: exon/intron organization and promoter activity. Genomics 1996, 35:156-163.
78. Yu H., Fukami K., Watanabe Y., Ozaki C., Takenawa T. Phosphatidylinositol 4,5-bisphosphate reverses the inhibition of RNA transcription caused by histone H1. Eur J Biochem 1998, 251:281-287.
79. Zhao K., Wang W., Rando O.J., Xue Y., Swiderek K., Kuo A., et al. Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. Cell 1998, 95:625-636.